Clinical

The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.

Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.

Understanding postural orthostatic tachycardia syndrome is important in order to improve prevention and outcomes.

Recently recognized by the World Health Organization, acute myeloid leukemia (AML) with t(7;12)(q36;p13) has previously been associated with MNX1 and ETV6 signaling, although MNX1::ETV6 fusion transcripts have only been confirmed in approximately half of cases.

Epcoritamab-bysp showed a 69% objective response rate and 62% complete response rate in older patients with large B-cell lymphoma who were ineligible for anthracycline-based therapy.

The study offers insights on how to counteract resistance to Bruton tyrosine kinase (BTK) inhibitors.

The 2023 National Health Interview Survey found that a significant portion of US adults experience post–COVID-19 condition, or long COVID, with some facing activity limitations.

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

The top 5 most-viewed content from this year's American Thoracic Society (ATS) 2024 International Conference featured an interview with Monica Kraft, MD, ASTF, and coverage of multiple respiratory and pulmonary medicine areas.

In the final part of our interview, Alice W. Lee, PhD, MPH, highlights the importance of addressing ovarian cancer care disparities and beyond by understanding cultural and behavioral factors and adopting a more disaggregated approach to research.

Patients with interstitial lung disease (ILD) experience significantly higher rates of fatigue and excessive daytime sleepiness than healthy individuals.

In part 2 of our interview, Alice W. Lee, PhD, MPH, of California State University, Fullerton, examines survival disparities between Hawaiian/Pacific Islander and Asian Indian/Pakistani patients with ovarian cancer and suggests areas for further research.

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of cognitive impairment, with a notably higher likelihood of developing non-amnestic mild cognitive impairment.

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, with key research presented on immune thrombocytopenia, hemophilia, and multiple myeloma.

Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among Black patients compared with clinical trials.

By reducing cytokine release syndrome and neurotoxicity, prophylactic tocilizumab could facilitate safe outpatient administration of bispecifics to treat multiple myeloma (MM), explained Robert Rifkin, MD.

A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.

A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved glucose metabolism, enhanced endothelial function, and potential antiatherosclerotic properties that collectively lower the risk of cardiac events.

A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce toxicity, according to Amir Ali, PharmD, BCOP.

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.

Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) management costs by 48% compared with a fixed starting dose (FSD) in US patients with ovarian cancer.